Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...
Massive Bio publishes landmark prospective study demonstrating AI-driven clinical trial matching at scale in 3,804 cancer ...
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute ...
The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...
BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today ...
The last time I spoke about Upstream Bio, Inc. (UPB) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this ...
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study.
INmune Bio, Inc. announced positive results from a double-blinded, randomized clinical trial named "MissionEB" for its product CORDStrom, aimed at treating Recessive Dystrophic Epidermolysis Bullosa ...
- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results